Athira Pharma (NASDAQ:LONA) Rating Increased to Outperform at Mizuho

Mizuho upgraded shares of Athira Pharma (NASDAQ:LONA) from a neutral rating to an outperform rating in a research report released on Thursday morning, MarketBeat reports. The brokerage currently has $10.00 target price on the stock.

Several other research firms have also weighed in on LONA. Weiss Ratings assumed coverage on shares of Athira Pharma in a research note on Wednesday, February 11th. They issued a “sell (d-)” rating on the stock. Wall Street Zen raised shares of Athira Pharma to a “hold” rating in a research note on Saturday, February 14th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $10.00.

Athira Pharma Price Performance

Shares of LONA opened at $5.53 on Thursday. Athira Pharma has a fifty-two week low of $2.20 and a fifty-two week high of $8.36.

About Athira Pharma

Athira Pharma, traded as LONA on the NASDAQ, is a clinical-stage biopharmaceutical company focused on discovering and developing small-molecule therapeutics intended to restore neuronal health and function in neurodegenerative and cognitive disorders. The company’s research approach centers on modulating pathways involved in synaptic repair and neurotrophic signaling to address underlying neuronal dysfunction rather than solely treating symptoms.

Athira’s lead investigational therapy is fosgonimeton (ATH-1017), a small-molecule candidate designed to potentiate hepatocyte growth factor (HGF)/MET pathway signaling with the aim of improving synaptic connectivity and cognitive performance in patients with conditions such as Alzheimer’s disease and related cognitive impairments.